Fiscal Year:
2002
Title:
LUCIFERASE DIRECTED SUBSTRATES FOR CELL REGULATION
Agency:
HHS
Contract:
1R43GM065670-01
Award Amount:
$99,850.00
Abstract:
DESCRIPTION (provided by applicant): This Small Business Innovation Research
Phase I project aims to investigate the feasibility of developing new compounds
capable of utilizing common marker gene expression in transformed cells to
control the growth and character of cells in living tissue. If successful, the
proposed research will provide breakthroughs needed to advance the promising
medical uses of recombinant genes. In Phase I of this project, Marker Gene
Technologies proposes to establish the feasibility of the technology by
preparing new D-luciferin conjugates of common growth regulators, drugs and
enzyme inhibitors, for administration to animal cells or bacteria that contain
either the firefly luciferase gene (luc) as a gene fusion marker. These new
conjugates will provide innovative methods of utilizing this reporter gene
system in transformed cells to affect drug delivery and control selected
biological properties. In Phase I, the new conjugates will be assayed in vitro
and in vivo for their ability to cause specific and localized inhibition or
improvement of cell growth and to deliver activated drugs in a cell- or
tissue-specific manner, In Phase II, the conjugates will be further tested in a
variety of significant medical applications.
Small Business Information at Submission:
MARKER GENE TECHNOLOGIES
MARKER GENE TECHNOLOGIES 3247 LINCOLN ST EUGENE, OR 97405
EIN/Tax ID:
931228900
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No